GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody, which has completed Phase IIb clinical trial for multiple sclerosis; and is in Phase IIa to treat type 1 diabetes, as well as is in Phase I for the treatment of chronic inflammatory demyelinating polyneuropathy. It has cooperative research and development agreements with The National Institute of Neurological Disorders and Stroke to develop novel therapeutic antibodies for the treatment of amyotrophic lateral sclerosis; and Academic labs to develop inflammatory psychosis, as well as a research collaboration agreement with International Center for Infectiology Research; and with Northwestern University for human endogenous retrovirus W envelope protein (HERV-W ENV) in long-haul COVID patients. The company was incorporated in 2006 and is headquartered in Plan-les-Ouates, Switzerland.

GeNeuro SA

GeNeuro is a biotechnology company developing innovative treatments against inflammatory and neurodegenerative disorders associated with Human Endogenous Retroviruses (HERVs).

We are committed to fight the progression of disability in Multiple Sclerosis #FightMS and other neurodegenerative diseases #ALS #LongCOVID

Our Community Guidelines: http://bit.ly/36y9YCE

European Investment Bank

Institut Merieux

Invesco

Eclosion SA

SRF (Switzerland) coverage on #longCOVID and the ongoing clinical trials to treat this condition, including Geneuro's #temelimab 
#postcovid #pasc #covidlong #covidpersistente #HERV

https://lnkd.in/e3BVsKCP

Recruitment is completed for our biomarker-based, randomized, placebo controlled, 200-patient Phase 2 trial of temelimab against neurological syndromes in #longCOVID. We are very grateful to the patients who have agreed to participate in this important study, and we also thank the teams of the 14 clinical centres for their great efforts in opening a new road. 

Completion of the ambitious recruitment objective in this new indication was an important milestone. We now look forward to sharing results next June and hope that this effort will result into a personalized medicine approach, allowing to identify and rapidly treat patients who may benefit from the therapy. 

#covidlong #PASC #temelimab #HERV

https://bit.ly/47MNZ81

Very excited to announce our partnership with Verily to combine our expertise in #HERVs #darkgenome with Verily’s high-resolution multi-omic#COVID19 data and state-of-the-art solutions to identify new genetic biomarkers to advance precision medicine.
#longcovid #covidlong #covidpresistente
https://shorturl.at/akryN

GeNeuro SA confirms its strong financial position and visibility, with financing of activities assured into Q3 2024.
https://lnkd.in/evEdb79k

We are pleased to announce that our CEO Jesús Martin Garcia will present at BioFuture!

Join us for our live presentation at the Lotte New York Palace in NYC on October 6th at 10:00 AM. For those attending virtually, our recorded presentation will be available online. Be sure to connect with us after you've watched our presentation!
https://biofuture.com

Discover #Temelimab, GeNeuro SA's approach aimed at treating neurologic symptoms in #LongCovid patients, currently in clinical trials in multiple centers in Italy, Switzerland, and  Spain (more information on https://t.ly/3Q9Ws !)

Great article showing the toxic impact of #HERV-W on the CNS and its potential role in #MS. Another evidence of the role of #HERVs in autoimmune diseases. #Longcovid #ALS
https://lnkd.in/eZ94m2Ft

Happy to share our recently published article in Translational Psychiatry, a Nature publishing group, resulting from a collaboration between our research team, the immuno-psychiatry team of the Hôpital Mondor in Créteil/Paris, and the I2MC platform. 

The article highlights the link between SARS-CoV-2 infection and the expression of the proinflammatory protein #HERV-W ENV. Our antibody targeting HERV-W ENV, #temelimab is currently on a clinical trial for #Longcovid

https://lnkd.in/e-xJApEi

EURONEXT:GNRO

GeNeuro

Last Close

0.07

26/07 12:28

Market Cap

3.33M

Beta: 0.32

Volume Today

11.45K

Avg: 7.39K

PE Ratio

−2.20

PFCF: −2.13

locale

market

industry

website

ipo date

peer of

Earnings

Earnings per Share (Estimate*)

Revenue (Estimate*)

Metrics